Hepatitis B Virus Reverse Transcriptase Polymorphisms Between Treated and Treatment-naïve Chronically Infected Patients

Overview

Journal Virusdisease

Publisher Springer

Specialty Microbiology

Date 2019 Jun 11

PMID 31179360

Citations 2

Authors

Masoumeh Rezanezhadi

Alireza Mohebbi

Fatemeh Sana Askari

Seyyede Delafruz Hosseini

Alijan Tabarraei

Affiliations

Soon will be listed here.

Abstract

The aim of this study was investigation of variation(s) in the Hepatitis B virus (HBV) reverse transcriptase domain. 120 patients with chronic HBV infection recruited. 104 patients were received nucleos(t)ide analogs treatments. DNA extractions were done from plasma samples. Direct sequencing and alignment of Polymerase Chain Reaction products were applied for further analysis. HBV genotypes determined by NCBI's Genotyping Tool. Polymorphism(s) were detected by using DnaSP software. Of 120 samples, 98 were sequenced. All of products were HBV genotype D. 13/98 (13.27%) of patients had M539I/V substitutions corresponding to YMDD motif. FLLAQ to FLMAQ was observed among 22/98 (22.98) patients. Two substitutions N459Y and L515M were significantly correlated (R = 0.486 and R = 0.941 respectively) with FLLAQ motif variation. Mutation ratio among treatment-received patients to treatment-naïve patients was 0.2-0.6. Drug resistance conferring substitutions (DRCSs) were rtL180M (22/98), rtA194V (11/98), rtM204V (1/98), and rtM204I (11/98). Furthermore, six variants were observed among all patients. Appearance of DRCSs in HBV polymerase is a major obstacle to the virus treatments. In the present study, it was shown that DRCSs are more prevalent among treated patients. Therefore, replacement of current anti-viral regimen with novel anti-HBV drugs is warranted in the future.

Citing Articles

Pharmacophore modeling and QSAR analysis of anti-HBV flavonols.

Baei B, Askari P, Askari F, Kiani S, Mohebbi A PLoS One. 2025; 20(1):e0316765.

PMID: 39804828 PMC: 11730388. DOI: 10.1371/journal.pone.0316765.

An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action.

Naderi M, Salavatiha Z, Gogoi U, Mohebbi A Front Cell Infect Microbiol. 2024; 14:1356003.

PMID: 38487354 PMC: 10937540. DOI: 10.3389/fcimb.2024.1356003.

A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study.

Mohebbi A, Ghorbanzadeh T, Naderifar S, Khalaj F, Askari F, Sammak A PLoS One. 2023; 18(5):e0285941.

PMID: 37196004 PMC: 10191303. DOI: 10.1371/journal.pone.0285941.

References

Han Y, Huang L, Liu C, Yang S, Li J, Lin Z . Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol. 2009; 24(8):1417-23. DOI: 10.1111/j.1440-1746.2009.05864.x. View

Librado P, Rozas J . DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009; 25(11):1451-2. DOI: 10.1093/bioinformatics/btp187. View

Gomes-Gouvea M, Ferreira A, Teixeira R, Andrade J, Ferreira A, Barros L . HBV carrying drug-resistance mutations in chronically infected treatment-naive patients. Antivir Ther. 2015; 20(4):387-95. DOI: 10.3851/IMP2938. View

Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R . Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat. 2007; 14(12):835-40. DOI: 10.1111/j.1365-2893.2007.00877.x. View

Lok A, Zoulim F, Locarnini S, Bartholomeusz A, Ghany M, Pawlotsky J . Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46(1):254-65. DOI: 10.1002/hep.21698. View

Moradi A, Zhand S, Ghaemi A, Javid N, Bazouri M, Tabarraei A . Mutations in pre-core and basal-core promoter regions of hepatitis B virus in chronic HBV patients from Golestan, Iran. Iran J Basic Med Sci. 2014; 17(5):370-7. PMC: 4069846. View

Nguyen M, Garcia R, Trinh H, Nguyen H, Nguyen K, Nguyen L . Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B. Aliment Pharmacol Ther. 2009; 30(11-12):1150-8. DOI: 10.1111/j.1365-2036.2009.04151.x. View

Tamura K, Stecher G, Peterson D, Filipski A, Kumar S . MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12):2725-9. PMC: 3840312. DOI: 10.1093/molbev/mst197. View

Moradi A, Zhand S, Ghaemi A, Javid N, Tabarraei A . Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran. Virus Genes. 2012; 44(3):382-7. DOI: 10.1007/s11262-012-0715-z. View

10.

Liu B, Li T, Xu J, Li X, Dong J, Yan P . Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res. 2009; 85(3):512-9. DOI: 10.1016/j.antiviral.2009.12.006. View

11.

Zhao Y, Wu J, Sun L, Liu G, Li B, Zheng Y . Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. Braz J Infect Dis. 2016; 20(2):173-8. PMC: 9427582. DOI: 10.1016/j.bjid.2015.12.006. View

12.

Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J . Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014; 30(2):252-61. DOI: 10.1111/jgh.12831. View

13.

Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T . A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004; 32(Web Server issue):W654-9. PMC: 441557. DOI: 10.1093/nar/gkh419. View

14.

Mohebbi A, Lorestani N, Tahamtan A, Kargar N, Tabarraei A . An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. Front Microbiol. 2018; 9:662. PMC: 5895781. DOI: 10.3389/fmicb.2018.00662. View

15.

Katoh K, Standley D . MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013; 30(4):772-80. PMC: 3603318. DOI: 10.1093/molbev/mst010. View

16.

Zoulim F, Locarnini S . Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137(5):1593-608.e1-2. DOI: 10.1053/j.gastro.2009.08.063. View

17.

Mohebbi A, Mohammadi S, Memarian A . Prediction of HBF-0259 interactions with hepatitis B Virus receptors and surface antigen secretory factors. Virusdisease. 2017; 27(3):234-241. PMC: 5394709. DOI: 10.1007/s13337-016-0333-9. View

18.

Lim Y . Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver. 2017; 11(2):189-195. PMC: 5347642. DOI: 10.5009/gnl15562. View

19.

Murakami E, Tsuge M, Hiraga N, Kan H, Uchida T, Masaki K . Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. J Infect. 2015; 72(1):91-102. DOI: 10.1016/j.jinf.2015.09.038. View

20.

Lee C, Lee H, Huang G, Yang P, Sheu J . Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol. 2006; 12(33):5301-5. PMC: 4088195. DOI: 10.3748/wjg.v12.i33.5301. View